Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer
Status:
Not yet recruiting
Trial end date:
2026-11-01
Target enrollment:
Participant gender:
Summary
This is a single arm, Phase II trial involving the use of atezolizumab plus platinum and
etoposide for patients with locally advanced urothelial cancer. The primary goal of this
trial is to assess the pathologic complete response rate at cystectomy in patients after
being treated with a combination therapy of atezolizumab, platinum, and etoposide.
Phase:
Phase 2
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins